Lateral flow urine lipoarabinomannan assay for tuberculosis diagnosis in HIV-positive inpatients and outpatients.
Giovana Rodrigues Pereira, Márcia Silva Barbosa, Carina Secchi, Maiara Priscila Dos Passos, André Kulzer Santos, Raimunda Sinthia Lima de Braga, Marina Scheffer de Souza, Gean Souza Ramos, João Vitor Vigne Duz, Denise Rossato Silva
Abstract
Open AccessOBJECTIVE: To evaluate tuberculosis diagnosis with the use of the lateral flow urine lipoarabinomannan assay (LF-LAM) in addition to the Xpert® MTB/RIF Ultra assay on sputum in HIV-positive inpatients and outpatients. METHODS: This was a prospective cross-sectional study including HIV-positive patients ≥ 18 years of age with an indication for LF-LAM in accordance with Brazilian National Ministry of Health criteria. RESULTS: A total of 140 patients were included in the study. LF-LAM was positive in 23 (16.4%). An additional 12 (8.6%) were diagnosed with the aid of LF-LAM, this increase in tuberculosis detection being statistically significant. LF-LAM-positive patients were younger and had lower CD4 counts in comparison with LF-LAM-negative patients. Smoking was more common among LF-LAM-negative patients than among LF-LAM-positive patients. CONCLUSIONS: The use of LF-LAM significantly increases the detection of tuberculosis in HIV-positive patients, mostly in those who are hospitalized. These findings highlight the utility of LF-LAM, especially in regions with high tuberculosis and HIV infection incidence.